Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18110705 | 1.00 | LTA4H (0.57) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| SCHEMBL2822843 | 1.00 | LTA4H (0.57) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| SCHEMBL1367956 | 1.00 | LTA4H (0.57) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Iodide SCHEMBL8989630 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Hydrochloric Acid SCHEMBL1367998 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Bromide SCHEMBL5857053 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Bromide SCHEMBL939381 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Bromide SCHEMBL1363188 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Hydrochloric Acid SCHEMBL18111693 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| SCHEMBL17472381 | 0.87 | CHRM3 (0.55) | LTA4HP2RX7CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100889-A1 | QUINAZOLINE DERIVATIVE, SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-05-15 | — | — | WO | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
| US-9895330-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895330-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-0823906-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034864-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0690713-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021254-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
| CN-1025852-C | Preparation of dizazbicyclic intermediates | PFIZER (US) | 1994-09-07 | — | — | CN | disclosed |
| EP-0397351-B1 | Preparation of diazabicyclic intermediates | PFIZER (US) | 1994-07-20 | — | — | EP | disclosed |
| US-5045549-A | Bactericides | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1991-09-03 | — | — | US | disclosed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | disclosed |
| CN-1047295-A | The preparation of diazabicyclo intermediate | PFIZER (US) | 1990-11-28 | — | — | CN | disclosed |
| EP-0324543-A2 | Antiarrhythmic agents | Pfizer Limited (GB) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | LTA4H 2545/4885P2RX7 4779/4885CHRNB2 127/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | LTA4H 659/4885P2RX7 4304/4885CHRNB2 1822/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | LTA4H 1994/4885P2RX7 247/4885CHRNB2 2141/4885 |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | LTA4H 1269/4885P2RX7 3476/4885CHRNB2 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.